$8.43
Today
as of Sep 4, 16:47 ET
Last 30 days
Recent Press Releases & News
CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference
CorMedix (CRMD) Upgraded to Buy: Here's Why
CorMedix (CRMD) Q2 2026 Earnings Call Transcript
Overview
52-week range
$6.13
$14
30% of range
Avg surprise (last 3)
+27.6%
Avg reaction (last 2)
+14.7%
100% positive
Latest IV / EM
72%
EM ±11.3% · $8 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $0.29 | — | — | — | — | financials |
| Thu May 14, 2026 | Mar/2026 | $0.43 | $0.35 | +22.9% | +43.3% | +5.7% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $1.26 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $0.28 | $0.20 | +40.0% | — | — | earnings |
| Tue May 6, 2025 | Mar/2025 | $0.30 | $0.25 | +20.0% | — | +23.6% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.05 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.25 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.25 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.17 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.25 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.24 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $102M | $127M | — | $104M | $40M | $39M | — | $11M |
| Cost of revenue | — | $12M | — | $8M | $2M | $2M | — | $634,650 |
| Gross profit | $77M | $105M | — | $93M | $38M | $37M | — | $11M |
| Operating income | $43M | $64M | — | $51M | $20M | $20M | — | $-3M |
| Net income | $26M | $39M | — | $109M | $20M | $21M | — | $-3M |
| EPS (diluted) | $0.29 | $0.43 | — | $1.26 | $0.28 | $0.30 | — | $-0.05 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $257M | $178M | $145M | $48M | $159M | $66M | $41M | $35M |
| Inventory | $39M | $31M | $30M | $29M | $10M | $7M | $8M | $7M |
| Total current assets | $481M | $383M | $367M | $260M | $248M | $145M | $115M | $73M |
| Total assets | $904M | $816M | $826M | $751M | $253M | $150M | $119M | $78M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $443M | $379M | $421M | $377M | $32M | $35M | $34M | $19M |
| Total equity | $461M | $437M | $405M | $374M | $221M | $115M | $85M | $59M |